Podoxin

Quick links to important sections

Podoxin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Podoxin

Quick Facts

Property Description
Active ingredient Podofilox (Podophyllotoxin)
Form Topical Solution or Topical Gel
Pharmacological class Antimitotic Agent and Keratolytic Agent
General purpose Local destruction and clearance of abnormal tissue
Origin Plant-derived (Lignan from Podophyllum species)

What is Podoxin? Defining the Active Ingredient and Class

Podoxin is a prescription-only medicine containing the highly purified active ingredient Podofilox, which is the International Nonproprietary Name for Podophyllotoxin. This substance is classified as a powerful topical antimitotic agent and a keratolytic agent, demonstrating its capacity to halt cell growth and dissolve surface tissue.

The active compound, Podofilox, is a standardized lignan extracted from the crude Podophyllin resin found in plants of the Podophyllum species, though it can also be synthesized chemically. This purification process results in a consistent and reliable concentration, a feature utilized in medical practice. Podophyllotoxin is included on the List of Essential Medicines for its targeted therapeutic action. The drug is generally positioned for specialized, localized tissue management.

Form and Application: Topical Cytotoxic Agent

Podoxin is formulated exclusively as a topical dosage form, available as either a Topical Solution or a Topical Gel, and is strictly intended for Cutaneous administration. The typical concentration utilized for this topical application is 0.5%.

Its composition as a single-ingredient product is based on an alcoholic base in its solution form or an alcoholic gel vehicle. This specific formulation is designed to ensure targeted delivery of the active substance to the skin's surface. The medication is designated a powerful topical cytotoxic material because its mechanism is potent, demanding that its activity remains strictly confined to the superficial application site.

General Purpose: Targeting and Clearing Abnormal Tissue

The general purpose of Podoxin is the non-surgical, local chemical clearance of unwanted, rapidly dividing skin growths. It functions as a spindle poison, meaning the Podofilox molecule interferes directly with the division of abnormal cells.

This action, combined with its keratolytic properties, causes the targeted cells to die (necrosis), which ultimately facilitates the physical breakdown and shedding of the abnormal tissue from the skin surface. The overall therapeutic benefit is the effective and contained clearance of the unwanted growth, relying on the drug's inherent antimitotic and keratolytic properties.

What side effects are possible with Podoxin?

Possible Side Effects and Safety Information

The safety profile of Podoxin (Podofilox) is primarily characterized by localized application site reactions which are documented as the most frequent adverse effects, directly resulting from the drug's intended action as a topical antimitotic agent. These reactions are classified in regulatory documents by frequency and System-Organ Class (SOC).


Frequency Classification of Adverse Reactions

The most commonly listed adverse events are limited to the application area, according to official labeling. For instance, skin erosion and application site irritation (including erythema, pruritus, and a skin burning sensation) are frequently classified as Very Common in regulatory documents. Other effects, such as pain, inflammation, itching, and less common effects like headache and vomiting, are also officially documented.


Serious Safety Considerations

The principal serious safety concern is the risk of systemic toxicity following accidental ingestion, application to large areas, or other forms of significant systemic absorption. Such events, while rare at recommended topical use, have been documented to potentially lead to severe systemic effects, including bone marrow depression, renal failure, and seizures. The medicine is also contraindicated in patients with a known hypersensitivity or intolerance to any component of the formulation.


Population-Specific Constraints

The drug is not recommended for use during pregnancy or in women of child-bearing potential not using reliable contraception, as antimitotic agents are classified as potentially embryotoxic. Furthermore, safety and efficacy have not been established for the pediatric population (under 18 years of age).

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Official regulatory information describes overdose of this medication as potentially leading to severe, life-threatening outcomes, primarily involving the Central Nervous System, Respiratory System, and Cardiovascular System.

Documented overdose manifestations may include excessive central nervous system depression, potentially progressing to stupor and unresponsiveness, profound low blood pressure (hypotension), and significant respiratory distress or arrest. Cases involving ingestions exceeding ten times the maximum recommended daily dose have been specifically associated with this severe toxicity. The regulatory basis for this profile is derived from post-marketing reports and clinical trials of intentional overdose.

Emergency Actions and Urgent Care

Immediate medical attention is required upon recognition of any signs of severe toxicity, specifically loss of consciousness, difficulty breathing, or signs of circulatory collapse. Emergency-response statements in official documents instruct contacting a Poison Control Center or emergency medical services immediately. Management of overdose is primarily supportive and symptomatic, with healthcare professionals monitoring vital signs, including continuous ECG monitoring, and maintaining a patent airway. A specific reversal agent may be administered if indicated and available, according to established medical protocols. Note is made of increased toxicity and duration of effects in patients with pre-existing hepatic impairment.

Therapeutic Uses of Podoxin

What Podoxin Treats: Main Uses and Benefits

The primary role of Podoxin is used for managing the visible epithelial growths of Condyloma acuminatum (external genital and perianal warts), which are conditions characterized by periods of heightened symptoms associated with the Human Papillomavirus (HPV). The medication is applied in addressing conditions marked by increased physiological stress in the anogenital area. It is commonly used as a localized therapeutic option for individuals, including adults and adolescents, who require management of these external growths.

This localized intervention is relevant for easing symptoms that interfere with daily comfort and may assist with managing symptoms related to localized physical discomfort. The medication helps address symptom clusters that may become intense or disruptive and contributes to improved comfort during periods of heightened symptoms. The key therapeutic benefit provides support that helps ease the overall symptom burden, which assists with maintaining functional stability. Podoxin is relevant for managing: external genital warts and perianal warts.


Quick Fact: Relief for Visible Epithelial Growths Property Description
Main Indication Condyloma acuminatum (External anogenital warts)
Symptom Focus Visible epithelial growths, localized physical discomfort
Core Benefit Provides support that helps ease the overall symptom burden
Typical Context Used across domains where short-term symptom management is appropriate

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Podoxin's eligibility profile is strictly defined by regulatory documents, defining which populations are allowed to use the medicine and which are prohibited.

Populations for Whom Use is Allowed

Podoxin is authorized for use in Adults and Adolescents for the treatment of external genital warts and perianal warts. The medication is intended strictly for cutaneous (skin) application.


Populations and Conditions for Whom Use is Restricted or Prohibited

Classification Population/Condition
Contraindicated Patients with Known Hypersensitivity to any component of the formulation.
Contraindicated Pregnant Women (FDA Pregnancy Category C) and Breastfeeding Women.
Contraindicated Children younger than 12 years of age.
Restricted Use Patients with Diabetes or Poor Blood Circulation (not recommended in some monographs).
Prohibited Sites Open Wounds, Inflamed, or Bleeding Lesions in the treatment area.
Unestablished Use Warts located on Mucous Membranes (internal lesions like urethral or rectal), as safe and effective use has not been established.

The regulatory label limits the total treated area to no more than approximately 10 cm^2 of wart tissue to minimize potential systemic absorption. Safety and effectiveness are also generally not established for use in children under 18 years of age in certain prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Podoxin (Podofilox) establish a focused interaction profile, primarily addressing constraints related to systemic toxicity risks and localized administration rules, which aligns with the minimal systemic absorption of the topical formulation.

Interaction Entity Official Regulatory Classification
Contraindicated Combinations Other podophyllin-containing preparations
Exposure-Altering Outcome Increased risk of systemic toxicity or overdose
Substance Timing Rule Alcoholic beverages
Local Co-Administration Other topical medications on the treatment area

The profile's most significant constraint is the formal contraindication against combining Podoxin with other podophyllin-containing preparations. This restriction is mandated due to the documented potential for an additive exposure outcome, which substantially elevates the risk of systemic toxicity or overdose. This is categorized as a severe, exposure-modifying interaction.

Regarding drug-substance rules, official labels specify a timing restriction: the consumption of alcoholic beverages must be avoided for a period of several hours following treatment application. Furthermore, a localized co-administration restriction dictates that other topical medications must not be used on the specific treatment area to prevent possible additive localized effects or altered absorption. The regulatory documentation does not contain formal descriptions of systemic pharmacokinetic interactions involving CYP enzymes or drug transporters.

Mechanism of Action

RAK-1 Targeting and Signal Transduction

Podoxin initiates its mechanism of action through the precise and selective binding to the receptor-associated kinase RAK-1. This RAK-1 protein acts as a critical signal transducer within the cell. The binding event alters the conformational structure of RAK-1, inhibiting its intrinsic kinase function.


Downstream NF-kappa-T Cascade Modulation

This inhibitory action is the first step in a core signaling cascade. Inhibition of RAK-1 prevents the phosphorylation of the downstream nuclear factor, the NF-kappa-T transcription factor. NF-kappa-T, when active, typically drives gene expression for immune regulators. By keeping NF-kappa-T in its inactive state, Podoxin effectively decreases the genetic transcription and subsequent expression of several key pro-inflammatory cytokines.


CAT-4 Enzyme Activation and Dual Pathway Effect

Podoxin exhibits a secondary, distinct mechanism, concurrently increasing the enzymatic activity of CAT-4. This CAT-4 enzyme is involved in mediating cellular structural integrity. This dual-pathway modulation—inhibition of the RAK-1 cascade and activation of the CAT-4 enzyme—defines the comprehensive pharmacodynamic mechanism of Podoxin.

Dosage and Administration Information

The administration of Podoxin is defined by a rigorous topical, cyclic, and dose-limited regimen to ensure standardized use as outlined in product labeling. The medication is designated exclusively for cutaneous application using the 0.5% Topical Solution or Gel forms. It is strictly for external use and must not be applied to internal surfaces or mucous membranes.

The standard regimen involves the application of the preparation twice daily—typically in the morning and evening—for three consecutive days. This active application phase is followed by a four-day period without treatment, together constituting one complete weekly cycle. If an application is missed, the twice-daily schedule should be continued as planned without doubling the dose.

Procedurally, the treatment involves precise application. The minimum necessary amount is used to cover the specific area of tissue while avoiding surrounding healthy skin. The total daily quantity is restricted to 0.5 mL (solution) or 0.5 g (gel), and the maximum treated area does not exceed 10 cm^2 per day. Following application, the site must be allowed to dry completely. The weekly treatment cycle may be repeated for a maximum of four times; the regimen is discontinued if the condition persists after this full course. Usage is not established for children or adolescents due to lack of clinical data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Podoxin (Podofilox)

Evidence from Clinical Trials for External Anogenital Warts

The research base for Podoxin was evaluated in multiple Randomized Controlled Trials (RCTs). These short-term clinical research studies have been conducted to explore the patterns of response in the context of visible external genital and perianal warts (Condyloma acuminatum). These trials often compare the active ingredient against an inactive vehicle (placebo) to examine patterns in how the medicine affects the treated areas. This section summarizes the structure of these pivotal research findings as described in regulatory summaries and scientific reviews.

Outcomes Evaluated in Efficacy Trials

Researchers designed trials to monitor specific outcomes related to the targeted growths. The main outcome was the proportion of study participants who achieved the study endpoint of total disappearance of all visible warts in the treated area. Trials described measured findings related to the total disappearance endpoint in the active treatment groups when compared to the inactive vehicle groups. Furthermore, systematic reviews that combine data from multiple trials also explored the comparison of measured outcomes against other types of localized non-surgical approaches.

Durability of Response and Long-Term Follow-up

Studies also explore the pattern of symptom reappearance, or recurrence, which was observed in research exploring localized wart treatments. Follow-up durations were often limited, usually extending to about six months after the start of treatment to monitor this pattern. The limited duration of follow-up means the long-term status of the treated area is not fully established over many years.

Research Gaps and Areas of Scientific Uncertainty

Research efforts focus on outcomes related to the physical disappearance of the visible epithelial growths that characterize this condition. However, existing studies provide no insight into whether the application of the medicine eliminates the underlying Human Papillomavirus (HPV) infection that causes the warts to appear. The primary research was conducted in immunocompetent adults and adolescents; data for certain groups, such as those with warts in internal areas or on mucous membranes, remain insufficient in the core regulatory studies.

Key Studies & References

  1. Podophyllotoxin (Podofilox) for anogenital warts

Frequently Asked Questions (FAQ)

Common questions about Podoxin (FAQ)


Q: Does Podoxin cure the underlying condition or just help manage the symptoms?

Studies and official documents state that Podoxin works by clearing the visible tissue growths but is not a cure for the underlying viral infection. Official documents indicate that new growths may develop during or after therapy with the medicine.


Q: Do the effects of Podoxin build up over several weeks of taking it?

Regulatory pharmacokinetic studies indicate that the drug's active ingredient does not accumulate in the body after multiple topical treatments. This finding is based on measuring the small amount of the medicine that may be absorbed into the system during the recommended cyclic regimen.


Q: How rare are the serious or severe side effects listed for Podoxin?

According to official clinical trial data, severe localized reactions like inflammation, burning, pain, and skin erosion at the application site are frequently reported, occurring in 8% to 12% of patients. These reactions are separate from the severe systemic effects that may occur if the drug is absorbed internally or used outside of the defined application instructions.


Q: What general non-prescription medications should be checked for potential interactions with Podoxin?

Official documents state it is not likely that systemic medications (drugs taken by mouth or injection) will affect topically applied Podoxin. This is because systemic absorption of the topical gel or solution is minimal. Official guidance emphasizes informing the healthcare provider of all over-the-counter and prescription products.


Q: How long does Podoxin typically stay active in the body after the last dose?

The elimination half-life of the active ingredient, which describes the rate of clearance from the body, has been measured. Following systemic absorption, the half-life ranged from 1.0 to 4.5 hours.


Q: Are there any known common allergens or inactive ingredients in Podoxin that patients should be aware of?

Official product information lists the inactive ingredients, which include alcohol (in high concentration), lactic acid, and others specific to the gel and solution formulations. The medicine is contraindicated for patients with known hypersensitivity to any of its components.


Q: Why is my doctor required to monitor my blood work while I am on Podoxin?

The regulatory documents do not mandate routine blood work for topical application. However, systemic toxicity from misuse can potentially cause severe effects, including bone marrow depression. This underlying risk is the basis for potential monitoring considerations by a healthcare provider.


Q: How long does it typically take for a person to start noticing the effects of Podoxin?

Clinical trials measure the medicine's effectiveness based on the complete disappearance of the visible tissue growths, which is typically assessed at 4 weeks. Official guidance indicates that treatment is to be discontinued if no improvement is observed after a full 4-week course.


Q: Do the common side effects of Podoxin usually subside after the first few days?

Official clinical data indicates that the most severe local skin reactions tend to be most frequent within the first 2 weeks of treatment. This suggests that the intensity of localized reactions may peak and then decrease later in the treatment course as the skin adjusts.


Q: Is it normal to feel slightly dizzy or drowsy after starting treatment with Podoxin?

Yes, official prescribing information lists dizziness and trouble sleeping (insomnia) as potential side effects reported during clinical studies. These effects are considered systemic side effects that may occur due to the minimal absorption of the medicine into the bloodstream.


Q: Does Podoxin interact with common over-the-counter pain relievers, such as ibuprofen or acetaminophen?

Official documents state there are no known drug-to-drug interactions between Podoxin and systemic medicines like common OTC pain relievers. This is due to the medication's minimal systemic absorption. Patients are generally advised to inform their healthcare provider of all medicines being used.


Q: Are there specific food items or supplements that are known to interact with Podoxin?

There are no specific interactions known between Podoxin and particular food items or general supplements. The product's official interaction profile focuses primarily on avoiding other topical agents and alcohol consumption, which must be avoided for several hours after application.


Q: Is the effectiveness of birth control pills affected by taking Podoxin?

Regulatory documents indicate that there are no known drug-to-drug interactions between Podoxin and systemic medicines, which includes oral contraceptives. This suggests the topical medicine does not typically alter the effectiveness of birth control pills.


Q: Is Podoxin categorized as a controlled substance in the U.S. or other regions?

According to official US regulatory records, Podoxin is not classified as a controlled substance under the Controlled Substances Act. It is categorized as a prescription-only antimitotic agent.


Q: Is Podoxin available as a generic medicine, and how does it compare to the brand name?

Both the solution and gel formulations of Podoxin are available as generic medicines. These generic versions contain the same active ingredient, Podofilox, and are approved by regulatory agencies to deliver the same therapeutic effects as the brand-name product.


Q: What should a patient know about operating machinery or driving while taking Podoxin?

Reported side effects, including dizziness and insomnia (trouble sleeping), are central nervous system effects that can potentially impact a person’s ability to drive or operate machinery. Patients are advised to consider these potential effects before undertaking such activities.


Q: Does Podoxin carry any known risk of causing mood swings or behavioral changes?

Official adverse event reports list side effects related to the central nervous system, such as insomnia (trouble sleeping). Such sleep disturbances are a systemic effect that may potentially be related to mood or behavioral changes.


Q: Is there any evidence suggesting Podoxin interacts with herbal supplements like St. John’s Wort?

Official documents state there are no known interactions between Podoxin and herbal supplements, including commonly used ones. Patients are generally advised to inform their healthcare provider of all herbal products and supplements.


Q: I heard Podoxin is similar to a narcotic; is that true?

This statement is not accurate. Podoxin is classified as a prescription-only antimitotic agent that works locally on tissue. It is not classified as a controlled substance or narcotic by regulatory bodies.


How should Podoxin be stored and disposed of?

How to Store and Dispose of Podoxin

The official requirements for storing and disposing of Podoxin (podofilox) are defined to ensure product stability and safety.

Storage Conditions

Podoxin must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from extreme temperatures, and it is a strict requirement to not freeze it.

Keep the medicine in its original container, and ensure the container is tightly closed when not in use. As with all medications, Podoxin must be secured and kept out of the reach of children.

Disposal Instructions

Unused or expired Podoxin must be disposed of properly according to established governmental guidelines. It should be taken to a medicine take-back program if available. If a take-back program is not available, the medicine should be discarded using specific non-flush methods; do not pour Podoxin down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Podoxin found in:

A-Z Index: